Anja Linnemann

Leading a Field Medical Strategy Team across US, Japan and Europe and covering strategic leadership for Field Medical employees (i.e. Medical Science Liaisons, Scientific Advisors, Field Medical Managers) across all Therapeutic Areas and all regions globally.

Leading strategic initiatives for Field Medical Teams (Medical Science Managers/Liaisons, Scientific Advisors and FM Managers) globally & across all Therapeutic Areas. Creation of procedural documents to standardize FM work. Coordination of internal/external Value Research (e.g. qualitative/quantitative HCP Research). X-functional cooperation with e.g. Commercial, Clinical Research, Regulatory, Legal & Compliance. Member of the Leadership Team: Worldwide Field Medical Excellence & Global Capability Hub.

Strategic medical matrix leadership for the Cardiovascular and Diabetes medical team in the EUM region (16 European countries); Covered compound Cardiovascular (in cooperation with Pfizer): FactorXa/Apixaban Covered compounds Diabetes (in cooperation with AstraZeneca): DPP4-I/Saxagliptin, GLP2-I/Dapagliflozin, GLP1/Exenatide

Medical communication and training activities for cardiovascular products (commercialized and pipeline) for the EMEA region

Medical responsibility for cardiovascular products in Switzerland

Scientific point of contact for external (physicians, payors, health authorities, vendors) and internal (crossfunctional deparments) customers; Interface between research and marketing; Global medical information and training responsibility; Safety officer according European MEDDEV guidelines;

Scientific point of contact for external (physicians, payors, health authorities, vendors) and internal (crossfunctional deparments) customers; Interface between research and marketing;

Biotechnologie, Mikrobiologie, Virologie, Biochemie, Physiologie